Encapsidated DNA Impurities

Encapsidated DNA impurities are non-target, product-related DNA fragments from the host cell genome or production plasmids that are inadvertently packaged inside the AAV capsid during manufacturing. Characterizing and controlling these impurities is critical, as they pose direct safety risks to patients, including the potential transfer of hazardous genetic material.

• High Sensitivity Requirement: The analytical method must be sensitive enough to detect very low levels of impurity sequences within a high background of the correct vector genome sequence.
• Robust Sample Preparation: The process of isolating the DNA from within the AAV capsids must be exceptionally clean and efficient. It must avoid shearing the DNA while also preventing any contamination from external, non-encapsidated DNA.
• Complex Bioinformatics: Analyzing the vast datasets generated by NGS requires a sophisticated and validated bioinformatics pipeline to accurately map sequences, identify impurities, and distinguish them from sequencing artifacts.

• Early Development: This analysis is a critical characterization activity. The goal is to use a method like NGS to gain a clear understanding of the profile of encapsidated impurities that the manufacturing process produces.
• Mid-Development: The consistency of the DNA impurity profile is demonstrated across multiple batches. The method is used to de-risk the process and to assess the impact of any process changes.
• Late-Stage / BLA Submission: For BLA submission, the manufacturing process must be demonstrated to consistently control these impurities to low levels. This must be supported by a comprehensive dataset and a scientific risk assessment justifying that the observed levels do not pose a safety risk to patients

• Patient Risk: The encapsidated impurity DNA could potentially contain and transfer active oncogenes or other harmful gene sequences to the patient. It could also code for unintended and potentially immunogenic proteins.
• Manufacturing Risk: High levels of encapsidated impurities are an indicator of a poorly controlled manufacturing process. This can result from suboptimal plasmid design, incorrect plasmid ratios during transfection, or excessive DNA fragmentation during cell culture and lysis.

• This attribute is a deep-dive analysis of the DNA content within the "full" particles counted by the Empty/Full Ratio.
• It is a critical component of the overall Vector Genome Integrity assessment, as it confirms not only that the intended genome is intact, but that other unwanted genomes are absent.
• The presence of these DNA impurities reduces the effective dose per particle, lowering functional potency

This is an area of very high regulatory interest and scrutiny for all AAV products. NGS is the regulatory and industry standard for comprehensive characterization of encapsidated DNA impurities.

The industry focus is on mitigating the formation of these impurities through careful process design (e.g., optimizing plasmids to remove unnecessary sequences) and demonstrating through characterization that the levels are consistently low and do not pose a safety risk.

• Gene Therapy Guidance (FDA/EMA): Regulatory guidance for gene therapies emphasizes the need for extensive characterization of the vector to ensure its safety and purity. This includes a thorough analysis of the genetic material contained within the final vector product.
• Purity and Impurities (ICH Q6B): The principles of ICH Q6B apply. Encapsidated DNA impurities are considered product-related impurities. They must be characterized, and the manufacturing process must be shown to control them.